# NIAGARA (NCT03732677)

> Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03732677
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Muscle Invasive Bladder Cancer
- Interventions: Durvalumab; Cisplatin; Gemcitabine
- Enrollment: 1063
- Primary outcome: Pathologic Complete Response (pCR) Rates at Time of Cystectomy
- Primary outcome: Event-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=niagara-nct03732677